ProfileGDS5678 / 1416705_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 88% 89% 89% 90% 89% 87% 83% 89% 90% 88% 85% 89% 86% 89% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.864188
GSM967853U87-EV human glioblastoma xenograft - Control 27.1107889
GSM967854U87-EV human glioblastoma xenograft - Control 37.0535589
GSM967855U87-EV human glioblastoma xenograft - Control 47.324290
GSM967856U87-EV human glioblastoma xenograft - Control 57.0786589
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.4970187
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.9572183
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.0647189
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.1481290
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.8197788
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.3111485
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.0424889
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.5394286
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.0313889